Micelles for relieving neurotoxicity as well as preparation method and application of micelles

By preparing micelles composed of L-cystine-(polyethylene glycol ester)2-(diselenopropionate)2 carrier and antioxidant active factors, the solubility and targeting problems of existing antioxidant active ingredients in neurons were solved, achieving the effects of alleviating neurotoxicity and prolonging lifespan under oxidative stress.

CN118948763AActive Publication Date: 2024-11-15HEFEI XUAN TECHNOLOGY CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411037705.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

Existing antioxidant active ingredients have problems such as poor water solubility, poor targeting, and poor gastrointestinal stability in alleviating neuronal oxidative stress. In particular, the blood-brain barrier hinders their function in the brain, leading to oxidative damage participating in the pathological process of neurodegenerative diseases.

Method used

A micelle designed to alleviate neurotoxicity was prepared by generating L-cysteine-(polyethylene glycol ester)2-(diselenopropionate)2 via esterification as a carrier, which was then assembled with antioxidant active factors such as schisandrin, curcumin, or resveratrol to form micelles loaded with antioxidant active factors. The synergistic antioxidant stress-relief effect of multiple disulfide bonds and diselenobonds was utilized.

Benefits of technology

This micelle exhibited good biocompatibility in the model organism *C. elegans*, reducing lipofuscin accumulation, enhancing antioxidant enzyme activity, decreasing lipid peroxides, prolonging lifespan, and slowly releasing antioxidant active factors under oxidative stress, effectively alleviating neurotoxicity and demonstrating significant anti-oxidative stress effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948763A_ABST
    Figure CN118948763A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine development, and particularly relates to a micelle for relieving neurotoxicity and a preparation method and application thereof. The preparation method of the micelle comprises the following steps: S1, preparing N, N '-bis (t-butyloxycarboryl)-L-cystine-(macrogol ester) 2-(diselenodipropionate) 2; s2, preparing L-cystine-(polyethylene glycol ester) 2-(diselenodipropionate) 2; s3, preparing a micelle for relieving neurotoxicity; furthermore, in order to improve and relieve neurotoxicity, anti-oxidation active factors such as schisandrin B and the like can be loaded. The micelle can relieve neurotoxicity caused by oxidative stress, and the micelle formed by loading schisandrin B has a better effect, so that the micelle can be used for efficiently preventing and treating neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine development, and specifically relates to a micelle for alleviating neurotoxicity, and a preparation method and application thereof. Background Art

[0002] Reactive oxygen species (ROS) refers to the general term for oxygen-containing free radicals and peroxides that are easy to form free radicals and are related to oxygen metabolism in the body. They are a type of single-electron reduction product of oxygen in the body, which is generated when electrons leak out of the respiratory chain before being transferred to the terminal oxidase and consume about 2% of oxygen.

[0003] Reactive oxygen is generated in various ways, mainly involving redox reactions in organisms, especially in organelles such as mitochondria and chloroplasts. The generation of reactive oxygen involves multiple organelles and metabolic pathways. Understanding the generation of reactive oxygen helps us better understand the role of reactive oxygen in organisms and its relationship with diseases.

[0004] When the redox balance in the body is disturbed, too much reactive oxygen will be produced. Brain neurons have a weak ability to scavenge free radicals. The high unsaturated fatty acid content, high oxygen consumption and relatively weak antioxidant defense mechanism of neurons make them extremely vulnerable to oxidative damage. Most single antioxidant active ingredients have the defects of poor water solubility, poor targeting and poor gastrointestinal stability. In particular, the blood-brain barrier also hinders the function of antioxidants. The oxidative damage caused by excess oxygen free radicals is directly involved in the pathological process of various neurodegenerative diseases such as Alzheimer's.

[0005] Therefore, it is urgent to develop substances that can alleviate neurotoxicity by resisting oxidative stress, so as to effectively prevent and treat neurodegenerative diseases. Summary of the invention

[0006] In view of this, the object of the present invention is to provide a micelle for alleviating neurotoxicity, wherein the micelle can alleviate the neurotoxicity caused by oxidative stress, and thus can be used for the efficient prevention and treatment of neurodegenerative diseases.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a micelle for alleviating neurotoxicity, wherein the micelle has a structure as shown in formula (I):

[0009]

[0010] Specifically, n in the structural formula (I) is 40 to 180.

[0011] Preferably, n is 45 in the structural formula.

[0012] In a second aspect, the present invention provides a method for preparing micelles for alleviating neurotoxicity, the preparation method comprising the following steps:

[0013] S1. Preparation of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2;

[0014] Dissolve N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2 and 3,3'-diselendipropionic anhydride in dichloromethane, add N,N'-dicyclohexylcarbodiimide to react at room temperature, remove insoluble matter and precipitate in ether, and dry in vacuum to obtain a crude product;

[0015] The crude product was completely dissolved in deionized water and then transferred to a dialysis bag, and dialyzed with deionized water as the dialysis medium to remove unreacted polyethylene glycol. The dialysate was collected and freeze-dried to obtain N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2;

[0016] S2. Preparation of L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2;

[0017] N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester)-2-(diselenodiprotate) 2 was dissolved in a mixed solvent of dichloromethane and trifluoroacetic acid, hydrolyzed at room temperature, precipitated in ether and then dried in vacuum to obtain L-cystine-(polyethylene glycol ester)-2-(diselenodiprotate) 2;

[0018] S3. Preparation of micelles to alleviate neurotoxicity;

[0019] L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 is completely dissolved in deionized water and then transferred to a dialysis bag. Deionized water is used as a dialysis medium for dialysis. The dialysate is collected and freeze-dried to obtain micelles that alleviate neurotoxicity.

[0020] Preferably, the preparation method further comprises the following steps:

[0021] S4. Encapsulate antioxidant activity factors;

[0022] The antioxidant active factors and L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 are dissolved in tetrahydrofuran, and the resulting solution is transferred to a dialysis bag. Deionized water is used as a dialysis medium for dialysis, and the dialysate is collected and freeze-dried to obtain micelles that encapsulate the antioxidant active factors and alleviate neurotoxicity.

[0023] Preferably, the method further comprises the step of preparing N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2, comprising:

[0024] The N,N'-bis(tert-butyloxycarbonyl)-L-cystine represented by formula (II) is subjected to esterification reaction with polyethylene glycol 2000, 4000 or 8000 under the action of N,N'-dicyclohexylcarbodiimide to obtain the product.

[0025]

[0026] Further preferably, the method further comprises the step of preparing 3,3'-diselenodiprolic anhydride, comprising:

[0027] The 3,3'-diselenodiproic acid represented by formula (III) is refluxed with acetyl chloride to obtain the product.

[0028]

[0029] Preferably, the mass ratio of the antioxidant active factor to the L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2 is 1:2-8.

[0030] Preferably, the antioxidant activity factor is selected from one or more of schisandrin, curcumin and resveratrol.

[0031] Preferably,

[0032] The mass ratio of the antioxidant active factor to the L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2 is 1:3,

[0033] The antioxidant activity factor is schisandrin B.

[0034] Preferably,

[0035] The reaction time at room temperature in step S1 is 12 to 48 hours.

[0036] The vacuum drying time in step S1 is 12 hours.

[0037] The dialysis time in step S1 is 72h.

[0038] The time of hydrolysis at room temperature in step S2 is 2 to 6 hours.

[0039] The dialysis time in step S3 is 72 h.

[0040] Preferably, in step S1, the molar ratio of the N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2 to the 3,3-diselenodiprolic anhydride is 68:163.

[0041] Preferably, in step S2, the molar concentration of the N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2 and the mixed solvent of dichloromethane and trifluoroacetic acid is 5.7 mmol / L.

[0042] More preferably, the volume ratio of dichloromethane to trifluoroacetic acid in the mixed solvent of dichloromethane and trifluoroacetic acid is 2:1.

[0043] Preferably, the molecular weight cut-off of the dialysis bag is 3500Da.

[0044] In a third aspect, there is provided a use of the micelles of the present invention in the preparation of drugs for alleviating neurotoxicity caused by oxidative stress.

[0045] In a fourth aspect, an oral medicine is provided, wherein the oral medicine comprises a safe and effective amount of the micelles described in the present invention.

[0046] In the present invention, a safe and effective amount refers to an amount of a compound or composition that is sufficient to significantly induce positive beneficial effects, preferably a positive beneficial effect of alleviating neurotoxicity caused by oxidative stress, including the beneficial effects disclosed herein in an independent or combined form, but the amount is low enough to avoid serious side effects, that is, to provide a reasonable benefit-risk ratio within the scope of reasonable judgment of the technician.

[0047] A fifth aspect provides use of the micelles of the present invention in the preparation of oral medicines.

[0048] Compared with the prior art, the beneficial effects of the present invention are:

[0049] The invention prepares a micelle containing multiple disulfide bonds and diselenide bonds and having synergistic anti-oxidative stress by deprotecting a substance obtained by esterifying N,N'-bis(tert-butyloxycarbonyl)-L-cystine with polyethylene glycol and 3,3'-diselenodipronic anhydride to obtain a carrier L-cystine-(polyethylene glycol ester)2-(diselenodipronic acid ester)2, and then assembling an antioxidant active factor with the carrier L-cystine-(polyethylene glycol ester)2-(diselenodipronic acid ester)2 to form a micelle loaded with the antioxidant active factor.

[0050] Since the occurrence and development of aging and neurodegenerative diseases are closely related to oxidative stress, wild-type (N2) Caenorhabditis elegans and its Alzheimer's mutant (CL4176) were selected as model organisms to evaluate the biosafety and anti-oxidative stress effects of micelles that alleviate neurotoxicity and micelles that embed antioxidant active factors to alleviate neurotoxicity. Studies have shown that micelles that alleviate neurotoxicity and micelles that embed antioxidant active factors to alleviate neurotoxicity have good biosafety and can not only reduce the accumulation of lipofuscin caused by normal aging in N2 type Caenorhabditis elegans, but also prolong the lifespan of nematodes and alleviate neurotoxicity by increasing the activity of antioxidant enzymes in nematodes and reducing the content of lipid peroxide malondialdehyde. The study further confirmed that after the Alzheimer's mutant (CL4176) was treated with neurotoxicity-alleviating micelles and neurotoxicity-alleviating micelles encapsulating antioxidant active factors, the increase rate of SOD and GSH-Px activities exceeded that of N2 type Caenorhabditis elegans, while the antioxidant enzyme activity was generally improved and the MDA content was reduced, further confirming the broad prospects of neurotoxicity-alleviating micelles and neurotoxicity-alleviating micelles encapsulating antioxidant active factors for the efficient prevention and treatment of neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 These are the hydrogen nuclear magnetic resonance spectra of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprotate) 2 (A) and L-cystine-(polyethylene glycol ester) 2-(diselenodiprotate) 2 (B).

[0052] Figure 2 Infrared spectra of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprotate) 2 (A) and L-cystine-(polyethylene glycol ester) 2-(diselenodiprotate) 2 (B).

[0053] Figure 3 The critical micelle concentration curves are shown for the micelles (A) prepared in Example 1 and the micelles @ Schisandrin B (B) prepared in Example 2.

[0054] Figure 4 The hydrodynamic diameter (D) of the micelle @ Schisandrae Chinensis B prepared in Example 2 before (A) and after (B) H2O2 treatment for 48 h h )Change curve graph.

[0055] Figure 5 Transmission electron micrographs of the micelles@Schisandrin B prepared in Example 2 before (A) and after (B) oxidation with H2O2 for 48 h.

[0056] Figure 6The release curves of the micelles @ Schisandrin B prepared in Example 2 in a normal physiological environment (A) and in the presence of H2O2 (B).

[0057] Figure 7 The survival curves of N2 type Caenorhabditis elegans (A) and CL4176 type Caenorhabditis elegans (B) that were untreated and exposed to the micelles prepared in Example 1, schisandrin B, and micelles@schisandrin B prepared in Example 2.

[0058] Figure 8 Fluorescence images of N2 type Caenorhabditis elegans without treatment (A) and after exposure to micelles prepared in Example 1 (B), schisandrin B (C), micelles@schisandrin B prepared in Example 2 (D), and a fluorescence intensity image of lipofuscin in nematodes (E).

[0059] Fig. 9 Fluorescence images of N2 type Caenorhabditis elegans without treatment (A) and exposed to micelles prepared in Example 1 (B), schisandrin B (C), and micelles@schisandrin B prepared in Example 2 (D), as well as a graph of the fluorescence intensity of ROS in the nematodes (E).

[0060] Fig.10 Fluorescence images of untreated CL4176 Caenorhabditis elegans (A) and those exposed to micelles prepared in Example 1 (B), schisandrin B (C), and micelles@schisandrin B prepared in Example 2 (D), as well as a graph of the fluorescence intensity of ROS in the nematodes (E).

[0061] Fig.11 CAT activity (A), SOD activity (B), GSH-Px activity (C) and MDA content (D) of N2 C. elegans exposed to the micelles prepared in Example 1, Schisandrin B, and micelles@Schisandrin B prepared in Example 2; N2 C. elegans not exposed to the samples served as the control group.

[0062] Fig.12 CAT activity (A), SOD activity (B), GSH-Px activity (C) and MDA content (D) of CL4176 Caenorhabditis elegans exposed to the micelles prepared in Example 1, schisandrin B, and micelles@schisandrin B prepared in Example 2; CL4176 Caenorhabditis elegans not exposed to the samples served as the control group. DETAILED DESCRIPTION

[0063] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0064] Example 1

[0065] This embodiment provides a method for preparing micelles for alleviating neurotoxicity, the preparation method comprising the following steps:

[0066] S1. Preparation of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2;

[0067] N,N'-bis(tert-butoxycarbonyl)-L-cystine-(polyethylene glycol ester) 2 (0.68 mM) and 3,3'-diselenodipronic anhydride (1.63 mM) were dissolved in 50 mL of anhydrous dichloromethane, N,N'-dicyclohexylcarbodiimide was added and reacted at room temperature for 48 h, insoluble matter was removed and precipitated in ether and the precipitate was collected, and vacuum dried at room temperature for 12 h to obtain a crude product, which was completely dissolved in deionized water and transferred to a dialysis bag (MWCO: 3500 Da), dialyzed with deionized water as the dialysis medium for 72 h to remove unreacted polyethylene glycol, the dialysate was collected and freeze-dried to obtain N,N'-bis(tert-butoxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodipronic acid ester) 2.

[0068] S2. Preparation of L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2;

[0069] N,N'-bis(tert-butoxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodipronate) 2 (0.12 mM) was dissolved in 21 mL of a mixed solvent of dichloromethane and trifluoroacetic acid (the volume ratio of dichloromethane to trifluoroacetic acid was 2:1), hydrolyzed at room temperature for 4 h and then rotary evaporated. The concentrate was precipitated in excess ether and then dried in vacuum to obtain L-cystine-(polyethylene glycol ester) 2-(diselenodipronate) 2.

[0070] S3. Preparation of micelles to alleviate neurotoxicity;

[0071] L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 is completely dissolved in deionized water and then transferred to a dialysis bag. Deionized water is used as a dialysis medium for dialysis. The dialysate is collected and freeze-dried to obtain micelles (referred to as micelles) that alleviate neurotoxicity.

[0072] like Figure 1 As shown in (A), the characteristic chemical shift of the methylene group in polyethylene glycol appears at 3.65 ppm. After esterification with 3,3'-diselendipropionate to form N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2, -Se CH2 CH 2 -、-SeCH2- CH2-The chemical shifts of the characteristic protons appeared at 2.85 and 3.10 ppm, indicating the successful preparation of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2. Figure 1 As shown in (B), at 1.43ppm (CH3)3 The chemical signal of C-proton disappeared, indicating that L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2 was successfully prepared.

[0073] The chemical structures of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 and L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 were further characterized by infrared spectroscopy. Figure 2 As shown in (A), the characteristic peaks of -COC-, -CH stretching vibration and terminal -OH of polyethylene glycol in N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 appear at 1113, 2884 and 3436 cm -1 In addition, 527, 805, 1700cm -1 The characteristic peaks attributed to -C-Se, -Se-Se-, and -C=O further prove the successful preparation of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2. After deprotection, the di-tert-butyloxycarbonyl group is deprotected to form a primary amine group, so Figure 2 As can be seen in (B), the asymmetric stretching vibration of -NH2 appears at 3566cm -1 , another 1650cm -1 The stretching vibration of primary amine -NH appears, 1061cm -1 CN stretching vibration appeared at the position, confirming that L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2 had been successfully prepared.

[0074] Wherein, the preparation steps of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2 include:

[0075] The N,N'-bis(tert-butyloxycarbonyl)-L-cystine represented by formula (II) is subjected to esterification reaction with polyethylene glycol 2000, 4000 or 8000 under the action of N,N'-dicyclohexylcarbodiimide to obtain the product.

[0076] The preparation steps of 3,3'-diselenodiprolic anhydride include:

[0077] The 3,3'-diselenodiproic acid represented by formula (III) is refluxed with acetyl chloride to obtain the product.

[0078]

[0079] Example 2

[0080] This embodiment provides a method for preparing micelles that encapsulate antioxidant active factors and alleviate neurotoxicity, and the preparation method comprises the following steps:

[0081] The antioxidant active factor schisandrin B (10 mg) and L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 (30 mg) prepared in Example 1 were dissolved in tetrahydrofuran, and the resulting solution was transferred to a dialysis bag and dialyzed for 72 hours using deionized water as the dialysis medium. After the dialyzation, the unencapsulated schisandrin B was filtered out, the filtrate was collected, and freeze-dried to obtain a powder that is the neurotoxicity-relieving micelle that encapsulates the antioxidant active factor (referred to as micelles@schisandrin B).

[0082] Example 3

[0083] This example provides drug loading and encapsulation efficiency measurements.

[0084] Prepare 0.05~10mg L -1 Schisandrin B-ethanol standard solution was measured for its ultraviolet absorbance at 216 nm, and a standard curve of Schisandrin B was obtained after linear fitting, as shown in the first formula:

[0085] First formula:

[0086] C (mg L -1 )=(A-0.1301) / 0.2102(R 2 =0.9936)

[0087] Wherein, C represents the concentration of Schisandrin B-ethanol standard solution, and A represents the ultraviolet absorbance of the standard solution at 216 nm.

[0088] The micelles for alleviating neurotoxicity prepared in Example 2 were dissolved in ethanol, and their ultraviolet absorbance at 216 nm was measured, and substituted into the first formula to calculate the mass of schisandrin B embedded in the micelles. The drug loading and encapsulation efficiency were calculated according to the second and third formulas.

[0089] Second formula:

[0090] Drug loading (%) = (mass of embedded Schisandrin B / mass of micelles prepared in Example 2) × 100%;

[0091] The third formula:

[0092] Encapsulation efficiency (%) = (mass of encapsulated schisandrin B / mass of initially added schisandrin B) × 100%;

[0093] Based on this calculation, the drug loading of schisandrin B is 31.2% and the encapsulation efficiency is 83.4%.

[0094] Example 4

[0095] This example verifies the micellization behavior.

[0096] To confirm the formation of micelles, the critical micelle concentrations of the micelles prepared in Example 1 and the micelles@Schisandrin B prepared in Example 2 were measured by fluorescence spectrometer. Pyrene was used as a fluorescent probe and an acetone solution of pyrene (5×10 -4 M). Take a certain amount of the solution and add it to the sample tubes. After evaporation for 2 h in the dark, add 4 mL of 5×10 -5 ~5×10 -1 mg mL -1 The micelles prepared in Example 1 or the micelles prepared in Example 2 @ Schisandrae Chinensis B were stirred overnight. The excitation wavelength was 350 nm, and the emission spectrum of 350-550 nm was measured, and the slit width was 2 nm. The critical micelle concentration (CMC) was calculated by the ratio of the fluorescence intensity at 383 and 372 nm (I 383 / I 372 ) as the ordinate and the logarithm of the micelle concentration (Log C) as the abscissa.

[0097] like Figure 3 As shown in (A), the CMC value of the micelles prepared in Example 1 is 44.6 mg L -1 This indicates that the micelles with 3,3'-diselendipropionic anhydride as the hydrophobic core and polyethylene glycol and cystine as the hydrophilic shell have good stability. Figure 3 As shown in (B), the hydrophobic Schisandrin B can generate hydrophobic interactions and hydrogen bonds with 3,3'-diselendipropionic anhydride, so that the CMC value of the micelles prepared in Example 2 is reduced to 19.3 mg L -1 , indicating that the encapsulation of hydrophobic schisandrin B can enhance the stability of micelles.

[0098] Example 5

[0099] In this example, particle size analysis was performed.

[0100] The oxidative stress microenvironment was set up to study the hydrodynamic diameter (D h The hydrodynamic diameter (D) of the micelles @ Schisandrae Chinensis B prepared in Example 2 before (A) and after (B) H2O2 oxidation for 48 h was measured by laser particle size Zeta potential instrument. h ) and polydispersity index (PDI).

[0101] like Figure 4As shown in (A), the micelles @ Schisandrin B prepared in Example 2 h The particle size of the micelles was 135 nm, and the polydispersity index (PDI) was only 0.266, indicating that the particle size distribution of the micelles was relatively uniform. The micelle size also increased significantly after 48 h of H2O2 oxidation. This is because the micelles were slowly oxidized to form selenious acid, which caused the new assembly to swell. The PDI eventually increased to 0.508, as shown in Figure 2. Figure 4 As shown in (B), oxidation changes the particle size distribution curve of the micelle from a single peak to a double peak, further confirming that exogenous oxidative stimulation can change the micelles @ Schisandrin B prepared in Example 2 and lead to the release of Schisandrin B.

[0102] Example 6

[0103] In this embodiment, microscopic morphology observation is performed.

[0104] 100 μL of the micelle @ schisandrin B solution prepared in Example 2 was dripped onto the carbon support film, and a transmission electron microscope (accelerating voltage 80 keV) was used to observe the microscopic morphology of the micelle @ schisandrin B prepared in Example 2. The test was conducted at 25°C.

[0105] To further confirm the effect of oxidative stimulation on the microscopic morphology of micelles, transmission electron microscopy was used to observe the microscopic morphology of micelles after different treatments. Figure 5 As shown in (A), the micelles @ Schisandrin B prepared in Example 2 have a clear core-shell structure without any treatment, and the average particle size is 235.18±6.83nm; after being oxidized by H2O2 for 48h, the original core-shell structure of the micelles is no longer visible, and a small amount of Schisandrin B nanoparticles appear in the field of vision while forming a new sheet-like assembly, as shown in FIG. Figure 5 As shown in (B); the above-mentioned changes in particle size and morphology of the micelles indicate that they are highly sensitive to oxidative stimulation. Such structural changes lay the foundation for the subsequent sustained release of schisandrin B at the site of oxidative stress.

[0106] Example 7

[0107] This example provides a demonstration of the release of antioxidant active ingredients.

[0108] The micelles@Schisandrin B powder prepared in Example 2 were dissolved in pH 7.4 PBS and pH 7.4 PBS containing H2O2 and then packaged in a dialysis bag with a molecular weight cutoff of 3500 (the concentration of the micelle solution was 1 mg mL -1 ), immersed in a beaker containing 200 mL of the corresponding solvent, 4 mL of dialysate was taken regularly and an equal amount of dialysate was added. After completion, the ultraviolet absorbance of the dialysate taken out was measured at 216 nm, and the cumulative release amount of schisandrin B was calculated according to the fourth formula:

[0109] The fourth formula:

[0110] Cumulative release (%) = (M t / M o )×100%;

[0111] Among them, M t 、M o They represent the release amount at time t and the total mass of schisandrin B embedded in the micelles, respectively.

[0112] like Figure 6 As shown in (A), the final release amount of Schisandrin B in the micelles@Schisandrin B prepared in Example 2 under normal physiological conditions is only 2.65±0.10%, and the release amount can be ignored, indicating that the micelles can avoid the side effects of active factors on normal tissues; Figure 6 As shown in (B), in the case of the micelles @ Schisandrae Chinensis B prepared in Example 2, the diselenide bond was oxidized to selenious acid under the physiological environment of oxidative stress containing H2O2, the micelles were broken, and Schisandrae Chinensis B showed a slow release trend, with a cumulative release amount of 66.21±1.80% at the end of the release. The above results show that the micelles @ Schisandrae Chinensis B prepared in Example 2 can respond to oxidative stimulation, thereby enabling the antioxidant active ingredients embedded therein to be slowly released.

[0113] Example 8

[0114] This example provides the effect of micelles on the survival rate of Caenorhabditis elegans.

[0115] The N2 and CL4176 type Caenorhabditis elegans at the L4 stage were transferred to a 24-well plate containing micelles (0.688 mg / mL) prepared in Example 1, schisandrin B (0.312 mg / mL) and micelles @ schisandrin B (1.0 mg / mL) prepared in Example 2, and 1 mL of PBS buffer and 10 μL of 5-fluorouracil (1.25 mg / mL) were added to the well plate. The Caenorhabditis elegans without sample was used as the control group. This time was recorded as day 0, and the plate was transferred once every two days. During this process, the number of deaths was observed and recorded until all nematodes died, and the nematode survival curve was drawn. The experiment was repeated three times and calculated according to the fifth formula.

[0116] The fifth formula:

[0117] Survival rate (%) = (number of surviving nematodes / total number of nematodes) × 100%;

[0118] Depend on Figure 7As shown in (A), the average lifespan, median lifespan and maximum lifespan of N2-type Caenorhabditis elegans exposed to micelles, schisandrin B and micelles@schisandrin B were all extended compared with the control group. Taking the maximum lifespan as an example, the maximum lifespan of the above three groups was extended by 9.09%, 9.09% and 27.27% compared with the control group (as shown in Table 1). Figure 7 As shown in (B), the life span of CL4176 Caenorhabditis elegans exposed to micelles, schisandrin B, and micelles@schisandrin B was also greatly extended. Compared with the control group, the extension rate of the maximum life span of the above three groups of nematodes was the most significant, reaching 11.11%, 11.11% and 33.33% respectively (as shown in Table 2). These results all confirm the biosafety of the two micelles prepared in Example 1 and Example 2, and also preliminarily prove the beneficial effect of micelles in extending the life span of nematodes. Moreover, the extension rate of the maximum life span of N2 type Caenorhabditis elegans and CL4176 Caenorhabditis elegans exposed to micelles@schisandrin B was particularly significant, that is, the effect of micelles@schisandrin B in extending the life span of nematodes was the most significant.

[0119] Table 1 Lifespan of N2-type Caenorhabditis elegans

[0120]

[0121] Table 2 Lifespan of CL4176 Caenorhabditis elegans

[0122]

[0123] Example 9

[0124] This example provides the determination of lipofuscin content.

[0125] L4-stage N2-type Caenorhabditis elegans were cultured in NGM plates containing micelles, schisandrin B, and micelles@schisandrin B samples for 10 days, anesthetized with 10mmol / L tetramisole hydrochloride, and fixed. Twenty randomly selected N2-type Caenorhabditis elegans from each group were photographed under a fluorescence microscope at excitation and emission wavelengths of 380nm and 430nm. ImageJ was used to analyze the fluorescence intensity of lipofuscin in the nematodes.

[0126] The fluorescent molecules of cell age pigment particles lipofuscin are generally considered to be the final product of lipid peroxidation. They increase with age, so they are also called aging pigments. Lipofuscin can be deposited in various tissues and organs. If it is deposited in the brain, it will cause neuronal damage and is one of the pathogenesis of Alzheimer's disease. The fluorescence intensity of nematodes is proportional to the content of lipofuscin in their bodies. Figure 8As shown in (A), (B), (C), (D), and (E), the fluorescence intensity of N2 type Caenorhabditis elegans after co-incubation with micelles, schisandrin B, and micelles@schisandrin B was in the following order: control group > micelles > schisandrin B > micelles@schisandrin B. In other words, micelles and micelles@schisandrin B can both clear the accumulation of lipofuscin caused by aging, indicating that micelles and micelles@schisandrin B can delay the pace of aging, and micelles@schisandrin B can delay the pace of aging more significantly.

[0127] Example 10

[0128] This example provides a qualitative determination of ROS content.

[0129] The experimental N2 and CL4176 Caenorhabditis elegans were washed three times with M9 buffer. Then, the 2',7'-dichlorofluorescein diacetate fluorescent probe (DCFA-DH) was diluted to 50μM, and 1mL of the fluorescent probe solution was added to each well of a 24-well plate. Next, the experimental nematodes were transferred to a 24-well plate, sealed and protected from light. After incubation in the dark at 20℃ for 1h, the nematodes were washed again three times with M9 buffer to remove the residual fluorescent dye. The washed nematodes were moved to a centrifuge tube and anesthetized with a pre-prepared 60μM levamisole solution (1mL). The liquid containing the nematodes was dripped onto a glass slide to make a sample, which was then moved to a laser confocal fluorescence microscope for photography. Fluorescence images were acquired at an excitation wavelength of 485nm. Twenty nematodes were randomly selected from each group for photography, and the relative fluorescence intensity was analyzed using ImageJ software.

[0130] ROS has a strong oxidative capacity and can bind to most macromolecules in the body, such as proteins, lipids, and DNA, thereby causing cell damage. The accumulation of cell damage is the main cause of aging. Fig. 9 As shown in (A), (B), (C), (D), and (E), the total reactive oxygen species (ROS) level in N2-type Caenorhabditis elegans was qualitatively determined by fluorescence imaging technology, and the order of fluorescence intensity was control group > micelles > schisandrin B > micelles@schisandrin B. Since the fluorescence intensity in the nematode body is proportional to the ROS concentration, it is proved that micelles and micelles@schisandrin B can effectively remove ROS in the nematode body, and micelles@schisandrin B has the best effect. Fig.10 As shown in (A), (B), (C), (D), and (E), for CL4176 type Caenorhabditis elegans, micelles and micelles@schisandrin B also showed the same excellent scavenging effect on ROS, indicating that micelles and micelles@schisandrin B have great potential to alleviate brain damage caused by reactive oxygen species by anti-oxidative stress; among them, micelles@schisandrin B had the best effect.

[0131] Embodiment 11

[0132] This example provides the determination of antioxidant enzyme activity and malondialdehyde (MDA) content.

[0133] The synchronized L1-stage N2-type Caenorhabditis elegans and CL4176-type Caenorhabditis elegans were exposed under the same conditions. The experiment ended after 10 days. The treated nematodes were collected, washed three times with M9 buffer to ensure cleanliness, and then transferred to sterile centrifuge tubes. 2 mL of PBS buffer was added to each tube, and two sterilized steel balls were placed as grinding media. The worm bodies were broken and evenly ground by vortex oscillation for 30 seconds, repeated three times, and repeated three times with an interval of 20 seconds. The suspension was made into a homogenate, and the whole process was carried out under low temperature conditions. Centrifuge at 8000r / min at 4°C for 10 minutes. The supernatant was collected and transferred to a new centrifuge tube for quantitative analysis of total protein. The superoxide dismutase (SOD) activity, catalase (CAT) activity, glutathione peroxidase (GSH-Px) activity and malondialdehyde (MDA) content were calculated by measuring the OD value. Each measurement was repeated three times. The above data were considered significant when P < 0.05 (*), highly significant when P < 0.01 (**), and extremely significant when P < 0.001 (***).

[0134] SOD can convert O2 - Decomposed into H2O2 and O2, CAT can further decompose H2O2 into H2O and O2; GSH-Px can catalyze the conversion of reduced glutathione into oxidized glutathione, and convert toxic peroxides into non-toxic hydroxyl compounds. This process can promote the decomposition of H2O2 and protect the structure and function of the cell membrane from interference and damage by peroxides. Fig.11 As shown in (A), (B), (C), and (D), as shown in Table 3, the antioxidant enzyme activity of N2 type Caenorhabditis elegans treated with micelles, schisandrin B, and micelles@schisandrin B was significantly improved compared with the control group, and the content of malondialdehyde (MDA), the end product of lipid peroxidation, was significantly reduced, especially the GSH-Px activity was increased by 70.64%, which means that micelles and micelles@schisandrin B can delay aging by increasing the antioxidant enzyme activity and inhibiting the content of lipid peroxides; among them, micelles@schisandrin B has the most significant effect in delaying aging.

[0135] Depend on Fig.12From (A), (B), (C), and (D), as shown in Table 4, after the CL4176 type of Caenorhabditis elegans was treated with micelles, schisandrin B, and micelles@schisandrin B, the increase rates of SOD activity and GSH-Px activity exceeded those of N2 type Caenorhabditis elegans, while the antioxidant enzyme activities were generally improved and the MDA content was reduced, further confirming the broad prospects of micelles and micelles@schisandrin B for the efficient prevention and treatment of neurodegenerative diseases; among them, micelles@schisandrin B was more effective in the prevention and treatment of neurodegenerative diseases.

[0136] Table 3 Changes in antioxidant enzyme activities in N2-type Caenorhabditis elegans

[0137]

[0138] Table 4 Changes in antioxidant enzyme activities in CL4176 nematodes

[0139]

[0140] Similarly, in order to further illustrate the beneficial effects of the present invention, the following embodiments are provided:

[0141] Example 2.1 is provided. Compared with Example 2, the difference of Example 2.1 is that the antioxidant active factor schisandrin of the present invention is replaced by curcumin;

[0142] Example 2.2 is provided. Compared with Example 2, the difference of Example 2.2 is that the antioxidant active factor schisandrin of the present invention is replaced by resveratrol;

[0143] Combined with the preparation method of the present invention, micelles for alleviating neurotoxicity that encapsulate antioxidant active factors were prepared, and tested according to the test methods of Examples 4, 5, 6, 7, 8, 9, 10, and 11. The effects of the micelles for alleviating neurotoxicity that encapsulate antioxidant active factors prepared in Examples 2.1 and 2.2 were observed. The results were similar to the effects of the micelles @ Schisandrin B prepared in Example 2 above.

[0144] Similarly, in order to further illustrate the beneficial effects of the present invention, the following comparative examples are provided:

[0145] A comparative example 2.1 is provided. Compared with Example 2, the difference of the comparative example 2.1 is that the mass ratio of the antioxidant active factor of the present invention to the L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 is adjusted to 1:1;

[0146] A comparative example 2.2 is provided. Compared with Example 2, the difference of the comparative example 2.2 is that the mass ratio of the antioxidant active factor of the present invention to the L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 is adjusted to 1:9;

[0147] Combined with the preparation method of the present invention, micelles encapsulating antioxidant active factors for alleviating neurotoxicity were prepared, and tested according to the test methods of Examples 8, 9, 10, and 11. The effects of the micelles encapsulating antioxidant active factors for alleviating neurotoxicity prepared in Comparative Examples 2.1 and 2.2 were observed. The results were the same as Figure 7-Figure 12 The experimental group of schisandra chinensis B was similar.

[0148] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.

[0149] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.

Claims

1. A micelle for alleviating neurotoxicity, characterized in that: The micelle has a structure as shown in formula (I):

2. The neurotoxicity-alleviating micelle according to claim 1, characterized in that: In the structural formula (I), n is 40 to 180.

3. A method for preparing micelles for alleviating neurotoxicity, characterized in that: The preparation method comprises the following steps: S1. Preparation of N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2; Dissolve N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2 and 3,3'-diselendipropionic anhydride in dichloromethane, add N,N'-dicyclohexylcarbodiimide to react at room temperature, remove insoluble matter and precipitate in ether, and dry in vacuum to obtain a crude product; The crude product was completely dissolved in deionized water and then transferred to a dialysis bag, and dialyzed with deionized water as the dialysis medium to remove unreacted polyethylene glycol. The dialysate was collected and freeze-dried to obtain N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2; S2. Preparation of L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2; N,N'-bis(tert-butyloxycarbonyl)-L-cystine-(polyethylene glycol ester)-2-(diselenodiprotate) 2 was dissolved in a mixed solvent of dichloromethane and trifluoroacetic acid, hydrolyzed at room temperature, precipitated in ether and then dried in vacuum to obtain L-cystine-(polyethylene glycol ester)-2-(diselenodiprotate) 2; S3. Preparation of micelles to alleviate neurotoxicity; L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 is completely dissolved in deionized water and then transferred to a dialysis bag. Deionized water is used as a dialysis medium for dialysis. The dialysate is collected and freeze-dried to obtain micelles that alleviate neurotoxicity.

4. The preparation method according to claim 3, characterized in that: The preparation method further comprises the following steps: S4. Encapsulation of antioxidant activity factors; The antioxidant active factors and L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 are dissolved in tetrahydrofuran, and the resulting solution is transferred to a dialysis bag. Deionized water is used as a dialysis medium for dialysis, and the dialysate is collected and freeze-dried to obtain micelles that encapsulate the antioxidant active factors and alleviate neurotoxicity.

5. The preparation method according to claim 4, characterized in that: The mass ratio of the antioxidant active factor to the L-cystine-(polyethylene glycol ester) 2-(diselenodiprolate) 2 is 1:2-8.

6. The preparation method according to claim 4, characterized in that: The antioxidant activity factor is selected from one or more of schisandrin, curcumin and resveratrol.

7. The preparation method according to claim 5, characterized in that: The mass ratio of the antioxidant active factor to the L-cystine-(polyethylene glycol ester) 2-(diselendipropionate) 2 is 1:3, The antioxidant activity factor is schisandrin B.

8. The preparation method according to claim 3, characterized in that: The reaction time at room temperature in step S1 is 12 to 48 hours. The vacuum drying time in step S1 is 12 hours. The dialysis time in step S1 is 72h. The time of hydrolysis at room temperature in step S2 is 2 to 6 hours.

9. Use of the micelle according to claim 1 in preparing a drug for alleviating neurotoxicity caused by oxidative stress.

10. The use according to claim 9, characterized in that: The drug is an oral drug.

Citation Information

Patent Citations

  • Preparation method of nano drug-loading micelle realizing reduction responsive drug release based on selenium bond and sulfur bond

    CN107441042A

  • Drug delivery material with pH and dual redox responsiveness and preparation method and application thereof

    CN108815536A

  • Temperature and redox-sensitive type drug delivery material connected by diselenide bonds and preparation and application thereof

    CN108976356A

  • Reductive degradable poly(ε-caprolactone) polymer with hydrophilic carboxyl group at both ends and drug delivery composition using the same

    KR101929828B1

  • Amphiphilic block polymer, chemoradiotherapy NANO sensitizer, and method for preparing same

    WO2023237060A1